RPG Life Sciences bets on API growth with new deals and capacity
RPG Life Sciences plans another API acquisition after two deals and a Rs.243 crore stake sale to InvAscent, per TradingView citing Moneycontrol.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RPG Life Sciences, a Mumbai-based drugmaker, is putting its API business at the center of its next growth phase, Managing Director Ashok Nair told Moneycontrol, as reported by TradingView. The company moved its API operations into a subsidiary, RPG Active Pharma, and brought in healthcare investor InvAscent, which took a 40 percent stake for Rs.243 crore. Two acquisitions lifted API capacity from 110 KL to 505 KL and the pipeline from 12 to 28 molecules.
The company is evaluating another purchase within 12 months and targets 25 percent annual API growth over five years. Newly acquired plants are expected to add Rs.70-80 crore in revenue over six months. Domestic formulations grew 11.6 percent in the September quarter, and second-quarter revenue rose 16.5 percent to Rs.211.6 crore with record adjusted EBITDA of Rs.50.1 crore.
why it matters
For investors, this is a strategic shift: RPG is trying to catch up with larger Indian API producers as Western drugmakers move contracts toward India. These plans remain management targets rather than results.
tags
instruments
sources
- RPG Life Sciences bets on API expansion to drive next growth phase, eyes more acquisitions — TradingView, 3 November 2026 at 09:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗